Prelamin A Does Not Promote Atherosclerosis or Vascular Smooth Muscle Loss

Insights

Full-length prelamin A does not promote atherosclerosis or vascular smooth muscle loss. This finding contrasts with progerin in Hutchinson-Gilford progeria syndrome (HGPS), suggesting prelamin A is not a driver of vascular aging.

Area of Science:

  • Cardiovascular Biology
  • Aging Research
  • Molecular Genetics

Background:

  • Hutchinson-Gilford progeria syndrome (HGPS) involves mutations in LMNA, leading to progerin production and vascular smooth muscle cell (VSMC) loss.
  • Accumulation of full-length farnesylated prelamin A may contribute to vascular pathology in physiological aging.

Purpose of the Study:

  • To investigate the impact of prelamin A accumulation on atherosclerosis and VSMCs.
  • To determine if prelamin A expression drives vascular aging.

Main Methods:

  • Utilized Lmna L648R/L648R mice expressing a prelamin A variant that cannot be processed to mature lamin A.
  • Crossed these mice with Ldlr-/- mice to induce hyperlipidemia and atherosclerosis on a high-fat diet.

Main Results:

  • No significant differences in atherosclerotic plaque or necrotic core areas were observed between mice expressing only prelamin A and those expressing only mature lamin A.
  • Exclusive prelamin A expression did not cause VSMC loss or adventitial thickening in hyperlipidemic mice with atherosclerosis.
  • Aortic vascular smooth muscle remained normal in aged Lmna L648R/L648R mice.

Conclusions:

  • Prelamin A does not appear to induce vascular smooth muscle loss.
  • Prelamin A accumulation does not promote atherosclerosis or drive vascular aging.
  • These findings differentiate prelamin A's role from the progerin variant in HGPS-related vascular pathology.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
923
Inflammation01:38

Inflammation

Overview
61.7K
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
366
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.5K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
314